To date, many hydrogels are available on the market, such as MaxGelTM, a human cell-cultured-derived ECM containing collagen, laminin, fibronectin, tenascin, elastin, proteoglycans and glycosaminoglycans [98,99], the HydroMatrixTM synthetic peptide that originates a nanofiber scaffold in response to changes in temperature or ionic strength [98,100], and the TrueGel3D platform, an animal origin-free polysaccharide hydrogel system validated for several applications, such as tumoral cyst and spheroid formation, as well as coculture of cancer and stroma cells [101,102]. The gene discussed is FN1; the disease is cancer.